ovarian cancer during the period 2018 to 2022. HRD was determined by Myriad myChoice test. The variables to be studied were: somatic mutation, and germline if positive by NGS, type of mutation, age at diagnosis, histology, stage, primary or interval surgery after neoadjuvant chemotherapy, response, PARPi, progression free survival (PFS), and allergy to chemotherapy.

**Results** The mean age at diagnosis of ovarian carcinoma was 62 years, with a predominance of 50% stage IIIC, and 80% of serous histology grade 3. 32% were HRD positive, with BRCA1 in 55%, BRCA2 in 10%, and the remaining 35% others of the RAD51C, BRIPI.

68% of cases received neoadjuvant chemotherapy, and only 50% were candidates for interval surgery. Primary surgery was performed in 32% of patients. Results: CR 38.4%, PR 53.5%, SD: 2% and progression 6.1%. Allergic reaction to chemotherapy occurred in 22% of the total.

38% of patients received PARPi as first-line maintenance.

In the group of patients who progressed to first line (49% of our series), PFS was higher in those with somatic line pathogenic variants, presenting a median of 18 months versus 10 months, (p=0.015).

**Conclusion** The results of our case series are compatible with those published in the literature, highlighting the increase in PFS in HRD+ patients who have received maintenance with PARPi. We found an increase of allergic reactions in patients carrying pathogenic germline variants, probably due to splicing-related mechanisms. These data should be cross-checked with other future studies.

Disclosures The authors made no disclosures. The study was funded by the Slovenian Research Agency (research program P3–0289).

**#270 IMMUNOPHENOTYPIC FEATURES AND BRCA1/2 MUTATIONS FROM HIGH-GRADE SEROUS CANCER: THE ROLE OF CYTOPATHOLOGICAL ASSESSMENT**

1,2Simona Miceska*, 1,2Erik škof, 3Srdjan Novakovic, 4Vida Stegel, 5Spela Smrkelj, 6Branko Čujeticanin, 2Anja Jericevic, 1Biljana Grcar Kuzmanov, 1Veronika Kloboves Prevcnik. 1Institute of Oncology Ljubljana, Ljubljana, Slovenia; 2University of Ljubljana, Ljubljana, Slovenia; 3University Medical Centre Ljubljana, Ljubljana, Slovenia; 4Faculty of Medicine Maribor, Maribor, Slovenia

10.1136/ijgc-2023-ESGO.550

**Introduction/Background** High-grade serous cancer (HGSC) is the most common and aggressive type of ovarian cancer, and it is often associated with ascites at presentation. The objective of our research was to evaluate the accuracy of cytopathology to identify immunophenotypic features of HGSC and BRCA1/2 mutations from ascites.

**Methodology** Forty-five patients with histologically confirmed primary HGSC and malignant ascites were included in our study. Immunocytochemistry (ICC) staining for PAX8, WT1, P53, P16, and Ki-67 was performed on cytopsins and cytoblocks prepared from ascites. Next-generation sequencing (NGS) was used to detect germline/somatic BRCA1/2 mutations in the ascites. Both ICC and NGS results were compared with immunohistochemistry (IHC) and NGS results from tissue blocks of the primary tumor. Cronbach α and χ2 statistics, respectively, were used.

**Results** ICC/IHC results for PAX8, WT1, P53, and P16 showed good reliability between cytopsins, cytoblocks, and tissue blocks (α > 0.75), whereas poor reliability and significant differences were observed for Ki-67 between ascites and tissue blocks (α < 0.26; p < .001 [Kruskal-Wallis]). For germline BRCA1/2 mutations, 100% concordance was confirmed, but only 14% concordance was confirmed for somatic mutations.

**Conclusion** Our results confirmed that cytopathology is an accurate method for identifying immunophenotypic features of HGSC and detecting germline BRCA1/2 mutations from ascites. However, further investigation is required for assessing the proliferation activity of HGSC in ascites and for detecting somatic BRCA1/2 mutations.

Disclosure The authors made no disclosures. The study was funded by the Slovenian Research Agency (research program P3–0289).